Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued to investors on Tuesday. The firm issued a sell rating on the stock.

CANF has been the topic of several other reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st.

Can-Fite BioPharma Price Performance

Shares of CANF stock opened at $1.51 on Tuesday. Can-Fite BioPharma has a one year low of $1.29 and a one year high of $4.69. The business’s 50 day simple moving average is $1.54 and its 200 day simple moving average is $2.04. The stock has a market capitalization of $5.35 million, a PE ratio of -0.84 and a beta of 1.33.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the quarter. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.